Nymox Pharmaceutical (NYMX) Announces Upcoming Presentation of NX-1207 Data at European Association of Urology Congress
3/15/2013 11:13:39 AM
HASBROUCK HEIGHTS, N.J., March 15, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that a presentation entitled "Clinical studies of NX-1207: Phase 3 Injectable for BPH" will be given at 3:45 p.m. March 17 during the 28th Annual European Association of Urology Congress in the Milano Congressi, Milan, Italy. NX-1207 is the Company's novel patented drug which is currently in Phase 3 trials for BPH and Phase 2 for localized prostate cancer.
comments powered by